2020
DOI: 10.36660/ijcs.20200078
|View full text |Cite
|
Sign up to set email alerts
|

Oral Contraceptives and Cardiovascular Risk: Adding Clinical Evidence to the Pathophysiology

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0
1

Year Published

2021
2021
2023
2023

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(4 citation statements)
references
References 7 publications
0
3
0
1
Order By: Relevance
“…Interestingly, the risk of hypertension associated with OC increased with age, duration of use, body mass and progestin potency [ 38 ]. Exogenous hormones are known to influence several physiological mechanisms implicated in blood pressure regulation, including the renin-angiotensin-aldosterone system (RAAS), endothelial function, the sympathetic nervous system, oxidative stress [ 39 ], and arterial stiffness [ 9 ].…”
Section: Discussionmentioning
confidence: 99%
“…Interestingly, the risk of hypertension associated with OC increased with age, duration of use, body mass and progestin potency [ 38 ]. Exogenous hormones are known to influence several physiological mechanisms implicated in blood pressure regulation, including the renin-angiotensin-aldosterone system (RAAS), endothelial function, the sympathetic nervous system, oxidative stress [ 39 ], and arterial stiffness [ 9 ].…”
Section: Discussionmentioning
confidence: 99%
“…32 Cardiovascular disorders in this study were indicated by a change in blood pressure, and blood pressure variation was obtained for each control, but cases of hypertension that made the participants need to stop taking the medication were not found. 33,34 There was no rejection of Pill A and B from the participants. This study used an open-label method, so the researchers and the subjects knew the investigated drug of this study.…”
Section: Original Articlementioning
confidence: 95%
“…Desde sua criação, foi evidenciada relação com o risco cardiovascular e, mesmo com o avanço na indústria farmacêutica em desenvolver combinações de menor risco e redução da mortalidade nas mulheres em uso dessa medicação, ainda são observados eventos como infarto agudo do miocárdio (IAM), tromboembolismo venoso (TEV) e acidente vascular cerebral (AVC) pelo seu efeito pró-coagulante 6 .…”
Section: Introductionunclassified